Comparing two methods for managing pain in inoperable pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of upfront endoscopic ultrasound-guided celiac ganglion neurolysis (CGN) and celiac plexus neurolysis (CPN) compared to a conventional step-up approach for managing pain in patients with inoperable pancreatic cancer. Patients experiencing significant tumor-related pain will be enrolled and assessed for pain relief and quality of life. The study aims to determine the optimal timing for these interventions to maximize pain control and minimize reliance on opioids. By focusing on patients with a Karnofsky performance status of 60 or higher, the study seeks to identify those who can benefit most from these pain management techniques.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age \>= 18 years old
2. Diagnosed to have inoperable pancreatic cancer
3. Presence of tumor pain (centrally located, constant, with no other obvious cause) with a VAS \>= 3
4. Karnofsky performance status \>= 60
5. Planned for EUS examination and/or biopsy of the pancreatic tumor

Exclusion Criteria:

1. Allergy to bupivacaine, or alcohol
2. Potentially operable after neoadjuvant therapy
3. Expected survival of less than 3 months
4. Patient who is already on opioids for pain control
5. Previous percutaneous or EUS-guided CGN/ CPN
6. Recurrent pancreatic tumors after operation
7. Uncorrectable coagulopathy
8. Inability or unwillingness to provide informed consent

Where it's running

• Prince of Wales Hospital
  Hong Kong, Hong Kong, Hong Kong Recruiting

Study contacts

• Study coordinator: Shannon Melissa Chan
• Email: shannonchan@surgery.cuhk.edu.hk
• Phone: 852-35052627

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Intra-arterial Y-90 Radioembolization for unresectable pancreatic cancer

  This study tests whether delivering Yttrium-90 microspheres directly into the arteries feeding unresectable pancreatic tumors is safe and tolerable while looking for early signs of effect.

  Recruiting Phase 1 National Medical Research Radiological Centre of the Ministry of Health of Russia · Obninsk · NCT07898683

• Microwave Ablation Feasibility for pancreatic and liver cancers guided by endoscopic ultrasound

  This study tests whether an ultrasound-guided microwave ablation device can be safely and effectively used in adults with locally advanced, unresectable, or metastatic pancreatic or liver cancers.

  Recruiting Banner Health · Gilbert, Arizona and 5 other locations · NCT07817147

• EUS-guided pancreaticobiliary procedures with the RIVOS access device

  This study tests how the RIVOS EUS access device performs during interventional procedures for pancreatic and bile duct problems in adults.

  Recruiting Orlando Health, Inc. · Orlando, Florida · NCT07696572

• SBRT plus maintenance therapy vs maintenance therapy alone in advanced pancreatic cancer

  This trial tests whether adding targeted SBRT to ongoing maintenance therapy helps people with unresectable pancreatic cancer live longer than maintenance therapy alone.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07600268

• New way to deliver Gemcitabine directly to pancreatic tumors in non-resectable pancreatic cancer

  This study tests a catheter-based method to deliver Gemcitabine straight into or near pancreatic tumors in locally advanced, unresectable cases.

  Recruiting Phase 1/2 Smartwise Sweden AB · Solna · NCT07575191

• Dual-target CAR-T therapy targeting mesothelin and CLDN18.2 for advanced pancreatic cancer

  This treatment will try sequential CAR‑T cell infusions that target mesothelin and CLDN18.2 in people with unresectable or metastatic pancreatic adenocarcinoma who have received prior systemic therapy.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07066995

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.